Wegovy produces roughly twice the weight loss of Saxenda. In the head-to-head STEP 8 clinical trial, people taking Wegovy lost an average of 15.8% of their body weight over 68 weeks, compared to 6.4% for those on Saxenda. Both medications work through the same biological pathway, but differences in their design make Wegovy substantially more effective and more convenient to use.
How Weight Loss Results Compare
The STEP 8 trial, published in JAMA in 2022, is the most direct comparison available. It enrolled adults with overweight or obesity who did not have diabetes and tracked them for 68 weeks. The results weren’t close: Wegovy nearly doubled Saxenda’s weight loss at every time point measured.
Among participants who had at least one weight-related health condition like high blood pressure, type 2 diabetes, or high cholesterol, the gap narrowed slightly but remained large. Wegovy reduced body weight by an average of 14.9%, while Saxenda achieved 7.4%. In practical terms, that means a 250-pound person with a weight-related condition could expect to lose about 37 pounds on Wegovy versus roughly 18 pounds on Saxenda over the same period.
Why Wegovy Works Better
Both medications are GLP-1 receptor agonists made by the same company, Novo Nordisk. They mimic a gut hormone that signals fullness to the brain, slows stomach emptying, and reduces appetite. The key difference is molecular engineering. Wegovy’s active ingredient has a half-life of about 160 hours, meaning it stays active in the body for days. Saxenda’s active ingredient has a half-life of roughly 13 hours, so it clears the body much faster.
That longer half-life is what allows Wegovy to be dosed once per week rather than once per day. It also means the drug maintains a more consistent level in the bloodstream, which likely contributes to its stronger appetite-suppressing effect. Both drugs were designed with a fatty acid attachment that helps them bind to a protein in the blood (albumin), extending their activity. Wegovy’s version was simply engineered more effectively for this purpose.
Weekly vs. Daily Injections
Wegovy is injected once a week. Saxenda requires a daily injection. For most people, this is a significant quality-of-life difference. Sticking with a daily injection over months or years is harder than remembering a weekly one, and real-world data reflects this. In the STEP 8 trial, Saxenda’s utilization in some real-world pharmacy analyses has been so low that researchers couldn’t even report meaningful adherence numbers for it.
Both medications require a gradual dose increase (titration) over several weeks to minimize side effects. With Saxenda, you start at a low dose and increase weekly until reaching the full dose over about five weeks. Wegovy follows a similar principle but spreads the increases out over a longer period, typically reaching the maintenance dose around month four or five.
Side Effects Are Similar but Not Identical
The side effect profiles overlap heavily because both drugs target the same receptor. Nausea, vomiting, and diarrhea are the most common complaints with either medication. In clinical trials, Wegovy caused nausea in about 44% of participants, diarrhea in 30%, and vomiting in 24%. These rates are generally higher than what Saxenda trials reported, though direct comparison is tricky because the studies used different populations and protocols.
Most gastrointestinal side effects with both drugs peak during the dose-increase phase and improve over time. The slower titration schedule with Wegovy is partly designed to ease this transition. If you’ve tried Saxenda and found the side effects intolerable, switching to Wegovy won’t necessarily solve that problem, since the same receptor is involved. But some people do tolerate one better than the other.
Cost and Insurance Coverage
Neither medication is cheap without insurance. Saxenda has a list price of about $1,349 per month. Wegovy’s list price runs higher, typically in the range of $1,300 to $1,700 per month depending on the dose and pharmacy. The real cost you pay depends entirely on your insurance plan, and coverage for weight management medications varies widely.
Insurance plans that cover one of these drugs don’t always cover the other. Some plans have tried Saxenda as a first-line option because of its longer track record (it was FDA-approved in 2014, while Wegovy launched in 2021). If your insurance requires you to try Saxenda first before approving Wegovy, that’s worth knowing. Manufacturer savings programs exist for both drugs but typically only apply if you have commercial insurance, not Medicare or Medicaid.
Who Each Drug Is Approved For
Both medications are FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition. Saxenda also has approval for adolescents aged 12 and older who meet obesity criteria and weigh more than 132 pounds. Wegovy has received similar pediatric approvals.
Neither drug is intended for short-term use. Weight tends to return after stopping either medication, so the expectation is ongoing treatment alongside diet and exercise changes. This makes the convenience gap between weekly and daily injections even more relevant over the long term.
Which One Should You Choose
On the evidence, Wegovy is the stronger option. It produces more weight loss, requires fewer injections, and stays active in the body longer. The main reasons someone might end up on Saxenda instead are practical: insurance won’t cover Wegovy, Wegovy is out of stock (supply shortages have been an ongoing issue), or a prescriber wants to start with the older, more established drug first.
If you have access to both and your insurance covers either one, the clinical data clearly favors Wegovy. The STEP 8 trial was designed specifically to answer this question, and the margin wasn’t subtle. For people who have already been on Saxenda with modest results, switching to Wegovy often produces additional weight loss, though individual responses vary.